Galantamine | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | |
Galantamine | hsa00190 | Oxidative phosphorylation | 1.00E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Galantamine | hsa00500 | Starch and sucrose metabolism | 1.67E-02 | 2 | O43451, P06737 | MGAM, PYGL | More | |
Galantamine | hsa00563 | Glycosylphosphatidylinositol (GPI)-anchor biosynthesis | 3.01E-02 | 1 | Q14442 | PIGH | More | |
Galantamine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
Galantamine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
Galantamine | hsa00730 | Thiamine metabolism | 5.29E-03 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
Galantamine | hsa00830 | Retinol metabolism | 3.49E-02 | 1 | P00325 | ADH1B | More | |
Galantamine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Galantamine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
Galantamine | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | |
Galantamine | hsa02010 | ABC transporters | 3.01E-02 | 1 | P45844 | ABCG1 | More | |
Galantamine | hsa03010 | Ribosome | 1.88E-02 | 6 | P62753, P25398, P32969, P62829, P18077, P36578 | RPS6, RPS12, RPL9, RPL23, RPL35A, RPL4 | More | |
Galantamine | hsa03020 | RNA polymerase | 3.59E-02 | 2 | P30876, P62487 | POLR2B, POLR2G | More | |
Galantamine | hsa04014 | Ras signaling pathway | 4.65E-02 | 3 | Q15311, P0DP23, P17612 | RALBP1, CALM1, PRKACA | More | |
Galantamine | hsa04071 | Sphingolipid signaling pathway | 1.94E-02 | 3 | Q9H228, P01375, Q9UQC2 | EDG8, TNF, GAB2 | More | |
Galantamine | hsa04114 | Oocyte meiosis | 2.15E-02 | 3 | P0DP23, P17612, Q13362 | CALM1, PRKACA, PPP2R5C | More | |
Galantamine | hsa04141 | Protein processing in endoplasmic reticulum | 4.88E-02 | 4 | P18848, O60337, P11142, P07900 | ATF4, MARH6, HSPA8, HSP90AA1 | More | |
Galantamine | hsa04144 | Endocytosis | 4.07E-03 | 5 | Q9H444, O75351, P42566, Q15438, Q14161 | CHMP4B, VPS4B, EPS15, PSCD1, GIT2 | More | |
Galantamine | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
Galantamine | hsa04213 | Longevity regulating pathway - multiple species | 2.85E-02 | 2 | Q9Y4H2, Q13547 | IRS2, HDAC1 | More | |
Galantamine | hsa04217 | Necroptosis | 1.57E-07 | 18 | P01568, P23458, Q13489, Q9NQC7, P42224, P07900, P08238, P15104, P05141, P01584, P0C0S5, Q6FI13, Q93077, Q13557, Q9H444, O43633, O75351, Q08752 | IFNA21, JAK1, BIRC3, CYLD, STAT1, HSP90AA1, HSP90AB1, GLUL, SLC25A5, IL1B, H2AFZ, H2AC18; H2AC19, HIST1H2AC, CAMK2D, CHMP4B, CHMP2A, VPS4B, PPID | More | |
Galantamine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.50E-02 | 3 | P17612, Q13362, P0DP23 | PRKACA, PPP2R5C, CALM1 | More | |
Galantamine | hsa04310 | Wnt signaling pathway | 1.79E-02 | 2 | P17612, P67870 | PRKACA, CSNK2B | More | |
Galantamine | hsa04340 | Hedgehog signaling pathway | 1.39E-04 | 4 | P49841, P17612, P22694, Q9Y496 | GSK3B, PRKACA, PRKACB, KIF3A | More | |
Galantamine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
Galantamine | hsa04611 | Platelet activation | 2.12E-02 | 2 | Q9Y490, P17612 | TLN1, PRKACA | More | |
Galantamine | hsa04613 | Neutrophil extracellular trap formation | 1.02E-04 | 8 | P11215, Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | ITGAM, HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Galantamine | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
Galantamine | hsa04657 | IL-17 signaling pathway | 4.48E-03 | 5 | P07900, P49841, P14780, P01375, P01584 | HSP90AA1, GSK3B, MMP9, TNF, IL1B | More | |
Galantamine | hsa04713 | Circadian entrainment | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Galantamine | hsa04720 | Long-term potentiation | 4.42E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Galantamine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | |
Galantamine | hsa04728 | Dopaminergic synapse | 1.55E-02 | 3 | P17612, Q13362, P0DP23 | PRKACA, PPP2R5C, CALM1 | More | |
Galantamine | hsa04740 | Olfactory transduction | 6.71E-03 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Galantamine | hsa04742 | Taste transduction | 3.91E-02 | 1 | P17612 | PRKACA | More | |
Galantamine | hsa04910 | Insulin signaling pathway | 1.91E-03 | 5 | P0DP23, P17612, P22694, P06737, P49841 | CALM1, PRKACA, PRKACB, PYGL, GSK3B | More | |
Galantamine | hsa04916 | Melanogenesis | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Galantamine | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
Galantamine | hsa04921 | Oxytocin signaling pathway | 1.84E-02 | 3 | P0DP23, P17612, Q96RR4 | CALM1, PRKACA, CAMKK2 | More | |
Galantamine | hsa04924 | Renin secretion | 1.09E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Galantamine | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
Galantamine | hsa04932 | Non-alcoholic fatty liver disease | 9.70E-03 | 4 | P18848, P01584, P13073, O15239 | ATF4, IL1B, COX4I1, NDUFA1 | More | |
Galantamine | hsa04970 | Salivary secretion | 2.20E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Galantamine | hsa04971 | Gastric acid secretion | 2.87E-02 | 2 | P17612, P0DP23 | PRKACA, CALM1 | More | |
Galantamine | hsa04976 | Bile secretion | 1.19E-03 | 4 | P17612, P22694, P08183, Q14032 | PRKACA, PRKACB, ABCB1, BAAT | More | |
Galantamine | hsa05012 | Parkinson disease | 2.53E-02 | 5 | O15239, P13073, P05141, P18848, Q13557 | NDUFA1, COX4I1, SLC25A5, ATF4, CAMK2D | More | |
Galantamine | hsa05016 | Huntington disease | 3.21E-02 | 5 | O15239, P13073, P30876, P62487, P05141 | NDUFA1, COX4I1, POLR2B, POLR2G, SLC25A5 | More | |
Galantamine | hsa05020 | Prion disease | 3.37E-03 | 7 | P13591, P01584, P11142, O15239, P13073, P18848, P05141 | NCAM1, IL1B, HSPA8, NDUFA1, COX4I1, ATF4, SLC25A5 | More | |
Galantamine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 3.80E-02 | 6 | O15239, P13073, P18848, P05141, P01584, Q13557 | NDUFA1, COX4I1, ATF4, SLC25A5, IL1B, CAMK2D | More | |
Galantamine | hsa05031 | Amphetamine addiction | 2.87E-02 | 2 | P0DP23, P17612 | CALM1, PRKACA | More | |
Galantamine | hsa05034 | Alcoholism | 8.54E-07 | 10 | P17612, Q13547, P0DP23, Q96RR4, Q93077, P58876, P62807, Q16778, O60814, P68431 | PRKACA, HDAC1, CALM1, CAMKK2, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Galantamine | hsa05110 | Vibrio cholerae infection | 2.11E-03 | 2 | Q99437, P17612 | ATP6V0B, PRKACA | More | |
Galantamine | hsa05134 | Legionellosis | 1.28E-02 | 3 | P01584, P68104, P11142 | IL1B, EEF1A1, HSPA8 | More | |
Galantamine | hsa05140 | Leishmaniasis | 1.56E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | |
Galantamine | hsa05162 | Measles | 4.02E-02 | 3 | P11142, P01584, Q9NP90 | HSPA8, IL1B, RAB9B | More | |
Galantamine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | |
Galantamine | hsa05171 | Coronavirus disease - COVID-19 | 9.72E-03 | 7 | P01584, P62753, P25398, P36578, P32969, P18077, P62829 | IL1B, RPS6, RPS12, RPL4, RPL9, RPL35A, RPL23 | More | |
Galantamine | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | |
Galantamine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | |
Galantamine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
Galantamine | hsa05212 | Pancreatic cancer | 2.87E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | |
Galantamine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
Galantamine | hsa05415 | Diabetic cardiomyopathy | 1.49E-03 | 10 | P17252, P05141, P14598, Q15080, O15239, Q16718, O14521, P13073, Q13557, P04406 | PRKCA, SLC25A5, NCF1, NCF4, NDUFA1, NDUFA5, SDHD, COX4I1, CAMK2D, GAPDH | More | |